Douglass Winthrop Advisors LLC Grows Position in Zoetis Inc. $ZTS

Key Points

• Douglass Winthrop Advisors LLC increased its stake in Zoetis Inc. by 3.5%, owning approximately 481,488 shares valued at $79.3 million as of their latest SEC filing.
• Several other hedge funds also adjusted their positions in Zoetis, with Portside Wealth Group increasing its stake by 24.7% and Tandem Investment Advisors increasing theirs by 100.3% during the first quarter.
• Analyst ratings for Zoetis have varied, with recent downgrades from Stifel Nicolaus and Leerink Partners, while Piper Sandler increased their price target and maintained an "overweight" rating.

Douglass Winthrop Advisors LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 3.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 481,488 shares of the company's stock after buying an additional 16,119 shares during the quarter. Douglass Winthrop Advisors LLC owned about 0.11% of Zoetis worth $79,277,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Portside Wealth Group LLC grew its stake in Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after buying an additional 6,672 shares during the last quarter. Tandem Investment Advisors Inc. grew its stake in shares of Zoetis by 100.3% in the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after purchasing an additional 198,089 shares during the last quarter. Flagship Harbor Advisors LLC grew its stake in shares of Zoetis by 31.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock valued at $1,217,000 after purchasing an additional 1,760 shares during the last quarter. Horizon Financial Services LLC purchased a new position in shares of Zoetis in the 1st quarter valued at approximately $380,000. Finally, Sage Rhino Capital LLC grew its stake in shares of Zoetis by 117.6% in the 1st quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock valued at $1,155,000 after purchasing an additional 3,791 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president directly owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.18% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ZTS has been the topic of several analyst reports. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, UBS Group reduced their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Zoetis currently has an average rating of "Moderate Buy" and an average price target of $202.43.

Zoetis Stock Performance

NYSE ZTS opened at $156.3180 on Friday. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The stock has a market cap of $69.28 billion, a price-to-earnings ratio of 26.91, a price-to-earnings-growth ratio of 2.50 and a beta of 0.88. The business has a fifty day moving average of $153.84 and a 200-day moving average of $158.64. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same period in the previous year, the firm posted $1.56 earnings per share. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.